Caligan Partners LP - Apr 28, 2022 Form 4 Insider Report for STANDARD BIOTOOLS INC. (LAB)

Role
10%+ Owner
Signature
Caligan Partners LP, By: /s/ David Edward Johnson, Partner
Stock symbol
LAB
Transactions as of
Apr 28, 2022
Transactions value $
$1,075,574
Form type
4
Date filed
5/2/2022, 07:44 PM
Previous filing
Apr 18, 2022
Next filing
May 10, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LAB Common Stock, $0.001 par value per share ("Common Stock") Purchase $66.2K +27.6K +0.3% $2.40 9.11M Apr 28, 2022 See footnote F1, F2, F5
transaction LAB Common Stock Purchase $658K +247K +2.71% $2.66 9.36M Apr 29, 2022 See footnote F2, F3, F5
transaction LAB Common Stock Purchase $351K +125K +1.34% $2.81 9.48M May 2, 2022 See footnote F2, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Price is the volume weighted average selling price of all sales by Caligan Partners LP ("Caligan") and David Johnson (together with Caligan, the "Reporting Persons") on the transaction date for prices ranging from $2.37 to $2.44.
F2 The securities reported herein are held by an affiliated fund and managed account of Caligan. David Johnson is a Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan.
F3 Price is the volume weighted average selling price of all sales by the Reporting Persons on the transaction date for prices ranging from $2.57 to $2.70.
F4 Price is the volume weighted average selling price of all sales by the Reporting Persons on the transaction date for prices ranging from $ 2.71 to $2.89.
F5 The Reporting Persons hereby undertake to provide upon request of the staff of the Securities and Exchange Commission full information regarding the number of shares sold at each separate price.

Remarks:

The Persons disclaim beneficial ownership in the securities reported on this Form 4 except to the extent of his or its pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that any of the Reporting Persons are the beneficial owner of such securities for purposes of Section 16 or for any other purpose.